Comparative Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of Adalimumab in Healthy Subjects

Inclusion Criteria: * Healthy female subjects of non-childbearing potential or healthy male subjects aged 18 to 55 years (inclusive at screening). * Have body weight between 65.0 to 90.0 kg and a body mass index between 20.0 to 29.9 kg/m2, inclusive. * Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. * Must be able to provide written informed consent, which must be obtained prior to any study related procedures. Exclusion Criteria: * Evidence or history of clinically significant or relevant pathology. * Have either active or latent tuberculosis. * Have received treatment with a monoclonal antibody or fusion protein within 9 months prior to administration and/or have evidence of immunogenicity from previous exposure to a monoclonal antibody or fusion protein. * Have a mental disease classified as serious by the Investigator. * Have received live vaccine(s) within 4 weeks prior to Screening or who will require live vaccine(s) between Screening and the final study visit. * Who intake alcoholic beverages more than 28 units per week. * Have taken medication with a half-life of \> 24 h within 4 weeks or 10 half-lives of the medication prior to investigational medicinal product administration. * Have donated \> 100 mL of blood or plasma within 4 weeks prior to investigational medicinal product administration. * Have participated in another study with an investigational drug within 4 weeks prior to investigational medicinal product administration. Subjects who have received treatment with a biological or immunosuppressive agent within 3 months of screening should also be excluded. * Subjects who are not able to consume standardized meals provided by the clinical study site during hospitalization. * Subjects who, in the opinion of the Investigator, are not likely to complete the study for whatever reason. * Involvement of any sponsor, study site/contract research organisation employee, Investigator or their close relatives. * Vulnerable subjects. * Pregnant or nursing women.